Endocrinology

Airdoc Technology (02251.HK) achieved remarkable success in 2023, accelerating its commercialization in an unparalleled way  

Retrieved on: 
Wednesday, April 10, 2024
Consensus, Glaucoma, Conditional sentence, University, Finance, RMB, Risk, Approximation error, Patient, Artificial intelligence, Medical device, National Health Commission, Optometry, Endocrinology, Dementia, Certification, Hyperthyroidism, Ageing, Capital Medical University, Software, MICCAI, Hypertensive retinopathy, Beijing Tongren Hospital, Neurology, Acceleration, Intelligence, Paratriathlon, Hospital, Research, Near-sightedness, Amblyopia, AI, MDR, Strabismus, Skin, AMD, Ranibizumab, Diagnosis, Peking University, Growth, Cardiology, Physical examination, News, Cataract, Diabetic retinopathy, Ophthalmology

In 2023, Airdoc Technology significantly accelerated its commercialization，while most of its peers were still in the experimental stage or early stages of commercialization.

Key Points: 
  • In 2023, Airdoc Technology significantly accelerated its commercialization，while most of its peers were still in the experimental stage or early stages of commercialization.
  • 2) health risk assessment solutions, covering 55 types of lesions, providing chronic disease management and health assessments for healthcare industry.
  • Airdoc Technology practices the use of AI technology to assist in the prevention and control of myopia among teenagers and the development of eye health.
  • In July 2023, Airdoc Technology participated in the formulation of the "Expert Consensus on Assessing the Risk of Cardiovascular Diseases Using Artificial Intelligence Technology Based on Fundus Images."

Bellabeat Unveils Next-Gen IVY Health Tracker for Women: A Leap Forward in Advanced Temperature Tracking and Wellness

Retrieved on: 
Tuesday, March 19, 2024
Research, Temperature, Health, Medicine, Frontiers Media, Menstrual cycle, IVY, Heart rate, Ovulation, Journal, Fertility, Pregnancy, Woman, Reproductive biology, Skin temperature, Machine learning, Menstruation, Map, Endocrinology, Birth control

San Francisco, California--(Newsfile Corp. - March 19, 2024) - In its latest endeavor to revolutionize women's health technology, Bellabeat has launched the new IVY+ Health Tracker.

Key Points: 
  • San Francisco, California--(Newsfile Corp. - March 19, 2024) - In its latest endeavor to revolutionize women's health technology, Bellabeat has launched the new IVY+ Health Tracker.
  • It is equipped with a sophisticated temperature tracking feature, marking a significant advancement in menstrual and fertility tracking.
  • In conjunction with the Bellabeat app, the IVY+ Health Tracker transforms biometric data into actionable wellness insights.
  • The combination of the IVY+ Health Tracker and the Bellabeat app creates a comprehensive health monitoring experience that extends beyond traditional tracking methods.

Sutter Health Announces Significant Investment in a New Advanced Multi-Specialty Neurosciences Care Complex in San Francisco’s Mission Neighborhood

Retrieved on: 
Thursday, April 4, 2024
Neurology, Diagnosis, Brain, Cardiology, Partnership, Physician, Health, Patient, SAN, Stroke, Research, Aneurysm, Elective surgery, Sutter Health, General surgery, Forbes Norris, Neurosurgery, Investment, Pediatrics, Hospital, Endocrinology, Podiatry, Graduate medical education, Rehabilitation, Nursing

The new Mission Bernal Care Complex, built on the site of the former St. Luke’s Hospital, will serve as an advanced, multi-specialty center for comprehensive neurological and neurosurgical care.

Key Points: 
  • The new Mission Bernal Care Complex, built on the site of the former St. Luke’s Hospital, will serve as an advanced, multi-specialty center for comprehensive neurological and neurosurgical care.
  • Finally, Sutter will expand primary care and women’s care services on the Mission Bernal Campus at the Monteagle building ( 1580 Valencia St .).
  • "At Sutter Health, the commitment to expanding access to high-quality care is unstoppable,” said Ken McNeely, Sutter Health board chair.
  • “This investment underscores the organization's dedication to meeting the health care needs of Northern California communities, ensuring that patients receive exceptional care close to home.

NORTHSHORE HEALTH CENTERS ANNOUNCES FOUR NEW FACILITIES TO PROVIDE MORE ACCESSIBLE HEALTHCARE FOR INDIANA RESIDENTS

Retrieved on: 
Monday, April 1, 2024
Substance abuse, Family, Communication, Environment, OB/GYN, Patient, Pharmacy, Travel, Mental health, Transport, North, Pediatrics, Proxemics, Chiropractic, Privacy, Endocrinology, Podiatry

The new locations will enable the company to provide accessible care to a wider patient base.

Key Points: 
  • The new locations will enable the company to provide accessible care to a wider patient base.
  • NorthShore currently has 20 locations —full-service clinics and primary care clinics, school-based clinics and locations within other community organizations — that provide medical, dental, vision, chiropractic, mental health and medication assistance through on-site pharmacies.
  • As with all locations within the NorthShore community, the new facilities will also provide affordable, quality telehealth care through video or phone calls for appointments with providers for nonemergency primary care, behavioral health and substance abuse treatment.
  • Calming rooms for both patients and staff in need of personal space or privacy during doctor consultations will also be located throughout each facility.

Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy

Retrieved on: 
Thursday, March 28, 2024
Synthetic media, Neuroscience, Growth, Urology, Partnership, Knowledge, Acquisition, Health Canada, Immunology, Investment, Safety, PMDA, Trilogy, Endocrinology, Generative

PRINCETON, N.J. and FRANKFURT, Germany, March 27, 2024 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies.

Key Points: 
  • PRINCETON, N.J. and FRANKFURT, Germany, March 27, 2024 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies.
  • The acquisition by Indegene Ireland, a subsidiary of Indegene Limited, augments Indegene’s depth of clinical and regulatory writing expertise for market authorization applications globally.
  • Trilogy Writing & Consulting is a Germany, UK, and US-based, medical writing consultancy with know-how in the development and delivery of clinical, regulatory, safety, and medical content.
  • It applies its expertise and unique approaches to deliver quality medical writing output.

Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy

Retrieved on: 
Wednesday, March 27, 2024
Seyfarth Shaw, Synthetic media, Neuroscience, Growth, Urology, Partnership, Knowledge, Acquisition, Health Canada, Immunology, Investment, Safety, PMDA, Trilogy, Endocrinology, Generative

PRINCETON, N.J. and FRANKFURT, Germany, March 27, 2024 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies.

Key Points: 
  • PRINCETON, N.J. and FRANKFURT, Germany, March 27, 2024 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies.
  • The acquisition by Indegene Ireland, a subsidiary of Indegene Limited, augments Indegene’s depth of clinical and regulatory writing expertise for market authorization applications globally.
  • Trilogy Writing & Consulting is a Germany, UK, and US-based, medical writing consultancy with know-how in the development and delivery of clinical, regulatory, safety, and medical content.
  • It applies its expertise and unique approaches to deliver quality medical writing output.

PhaseV to Present at Upcoming Clinical Trial Events and Scientific Meetings, Highlighting the Value of Machine Learning in Drug Development

Retrieved on: 
Monday, April 8, 2024
ChromeOS, Post hoc analysis, Endocrinology, Insulin, Pharmaceutical industry

BOSTON, April 8, 2024 /PRNewswire/ -- PhaseV, a pioneer in causal machine learning (ML) for clinical trial analysis and optimization, announced today that company executives will present at five upcoming leading industry events in May and June.

Key Points: 
  • - Recruitment Optimization in Clinical Trials: Looking Towards an Adaptive Future
    Presentation: Abstract by Oramed Pharmaceuticals and PhaseV on Machine Learning-Based Optimization of Patient Eligibility for Oral Insulin Treatment: A Post Hoc Analysis of Phase III Trial Results
    PhaseV's platform leverages proprietary causal inference and machine learning tools to enable retrospective analysis of Phase 2 and Phase 3 trials to 'rescue' failed assets and/or optimize an analysis in order to better prepare for the next trial.
  • The platform also enables prospective design and execution of dynamic adaptive clinical trials by allowing users to quickly evaluate millions of options—taking specific considerations and constraints into account—and select the optimal choice.
  • This ML-driven adaptive process can significantly accelerate the clinical drug development process and increase certainty along the way, resulting in more efficient, targeted, and ultimately more successful clinical trials.
  • PhaseV's solutions are used by global pharma companies, biotech innovators, and CROs across a wide range of therapeutic indications, including oncology, endocrinology, autoimmune diseases, rare diseases, and more.

Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients

Retrieved on: 
Tuesday, March 19, 2024
Arthralgia, Abdominal pain, Acromegaly, Headache, Webcast, Patient, Diarrhea, NDA, FISU World University Games, ID, Endocrinology, Food, Medical school, Pharmaceutical industry

SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced positive topline results from PATHFNDR-2, the second of two Phase 3 studies evaluating the efficacy and safety of oral, once-daily investigational paltusotine for the treatment of acromegaly.

Key Points: 
  • “This study demonstrates that paltusotine can provide both symptom control as well as biochemical control in patients who are not currently on pharmacologic treatment.
  • The frequency of participants with at least one treatment emergent adverse event (TEAE) was comparable in the paltusotine treatment arm and placebo arm.
  • The frequency of adverse events considered related to acromegaly was notably lower in paltusotine treated participants compared to placebo treated participants.
  • Following the live event, a replay will be available on the Investors section of the Company’s website.

Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 14, 2024
Administration, Growth, Nitisinone, Patent, Patient, NDA, Orange Book, Trial of the century, Diurnal, Carglumic acid, Research and development, FDA, Endocrinology, Physician, Pharmaceutical industry

Eton reported fourth quarter 2023 product sales and royalty revenue of $7.3 million, representing a 109% year-over-year increase and 4% growth over the third quarter of 2023, driven primarily by the ongoing momentum of ALKINDI SPRINKLE and Carglumic Acid.

Key Points: 
  • Eton reported fourth quarter 2023 product sales and royalty revenue of $7.3 million, representing a 109% year-over-year increase and 4% growth over the third quarter of 2023, driven primarily by the ongoing momentum of ALKINDI SPRINKLE and Carglumic Acid.
  • Eton generated $0.4 million of operating cash during the fourth quarter of 2023, with total cash and cash equivalents of $21.4 million as of December 31, 2023.
  • Total net revenues were $7.3 million for the fourth quarter of 2023, compared to $8.5 million for the fourth quarter of 2022.
  • As previously announced, Eton Pharmaceuticals will host its fourth quarter 2023 conference call as follows:

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 28, 2024
Oncology, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Diagnosis, De novo, PIN, Obesity, MRI, Syndrome, Metabolism, KCH, Knowledge Organization (journal), International, National Health Service, NHS, Research, Radiology, MASH, Trial of the century, International Classification of Diseases, Hepatology, World Health Organization, Data collection, Prediabetes, NDRA, Liver, Type 2 diabetes, Liver disease, Marketing, NAFLD, Endocrinology, Video game

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three months and year ended December 31, 2023 and provides a business update.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three months and year ended December 31, 2023 and provides a business update.
  • Highlights from the fourth quarter of 2023 and recent weeks include:
    Installed first TAEUS system in the UK at King’s College Hospital for clinical evaluation.
  • In the third quarter of 2023, ENDRA submitted a De Novo request for its TAEUS liver system to the FDA.
  • In the fourth quarter of 2023, the FDA issued an Additional Information (AI) request to ENDRA.